Similarities and differences in affinity and binding modes of tricyclic pyrimido- and pyrazinoxanthines at human and rat adenosine receptors

Bioorg Med Chem. 2016 Sep 15;24(18):4347-4362. doi: 10.1016/j.bmc.2016.07.028. Epub 2016 Jul 18.

Abstract

A new series of 32 pyrimido- and 5 tetrahydropyrazino[2,1-f]purinediones was obtained and evaluated for their adenosine receptors (ARs) affinities. The 1,3-dibutyl derivative of 9-(4-(2-(dimethylamino)ethoxy)phenyl)-6,7,8,9-tetrahydropyrimido[1,2-f]purine-2,4(1H,3H)-dione was found to be the most potent A1 AR antagonist of the present series, showing selectivity over the other AR subtypes. The structure-activity for the obtained purinediones was established. Docking experiments of the investigated library to homology models of the human and rat A1 and A2A ARs allowed to compare the expected binding modes for selected compounds. The detailed analysis of binding cavities within individual AR subtypes indicated small but significant structural variations that may underlie the observed differences in binding affinities of purinediones at particular subtypes and species.

Keywords: Adenosine receptor; Docking; Homology modeling; Purine-2,6-dione; Species differences; Subtype selectivity; Xanthines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Binding Sites
  • CHO Cells
  • Carbon-13 Magnetic Resonance Spectroscopy
  • Cricetulus
  • Humans
  • Proton Magnetic Resonance Spectroscopy
  • Rats
  • Receptors, Purinergic P1 / drug effects*
  • Receptors, Purinergic P1 / metabolism
  • Sequence Homology, Amino Acid
  • Spectrophotometry, Infrared
  • Structure-Activity Relationship
  • Xanthines / chemistry
  • Xanthines / metabolism*
  • Xanthines / pharmacology

Substances

  • Receptors, Purinergic P1
  • Xanthines